PXL770

PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD) -fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH) [1][2][3].

Product Specifications

CAS Number

[1523493-53-9]

UNSPSC

12352005

Target

AMPK

Type

Reference compound

Related Pathways

Epigenetics; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease; Cardiovascular Disease; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pxl770.html

Concentration

10mM

Purity

99.56

Solubility

DMSO : 120 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(C(O)=C1C3=CC=CC=C3)C(C4=C(O)C(CCCC5)=C5C=C4)=C(Cl)S2

Molecular Formula

C23H18ClNO3S

Molecular Weight

423.91

References & Citations

[1]Monternier PA, et al. Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy. J Pharmacol Exp Ther. 2022 Aug;382 (2) :208-222.|[2]Gluais-Dagorn P, et al. Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis. Hepatol Commun. 2022 Jan;6 (1) :101-119. |[3]Dagorn PG, et al. A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.